The FDA concludes that the cholesterol-lowering drugs simvastatin (Zocor),ezetimibe (Zetia), and Vytorin (ezetimibe/simvastatin) are not likely to increase cancer risk.
Nadine M. Hasenecz
Advertisement
Articles by Nadine M. Hasenecz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Long-Acting Growth Hormone Analogs: Beyond Convenience to Individualized Care
2
Real-World Registries vs Clinical Trials in Long-Acting Growth Hormone Therapy
3
Chronic Liver Disease: How PCPs Can Improve Early Detection
4
Early Signs of Scarring Alopecia, Pipeline Outlook, With Bejamin Ungar, MD
5